| 000 | 01844 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250516033736.0 | ||
| 264 | 0 | _c20110824 | |
| 008 | 201108s 0 0 eng d | ||
| 022 | _a1558-3597 | ||
| 024 | 7 |
_a10.1016/j.jacc.2011.02.022 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aStone, Gregg W | |
| 245 | 0 | 0 |
_aRandomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial. _h[electronic resource] |
| 260 |
_bJournal of the American College of Cardiology _cJun 2011 |
||
| 300 |
_a19-25 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Multicenter Study; Randomized Controlled Trial | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aCoronary Restenosis |
| 650 | 0 | 4 | _aDrug-Eluting Stents |
| 650 | 0 | 4 | _aEverolimus |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xadministration & dosage |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPaclitaxel _xadministration & dosage |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 |
_aSirolimus _xadministration & dosage |
| 650 | 0 | 4 |
_aThrombosis _xprevention & control |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aTubulin Modulators _xtherapeutic use |
| 700 | 1 | _aRizvi, Ali | |
| 700 | 1 | _aSudhir, Krishnankutty | |
| 700 | 1 | _aNewman, William | |
| 700 | 1 | _aApplegate, Robert J | |
| 700 | 1 | _aCannon, Louis A | |
| 700 | 1 | _aMaddux, James T | |
| 700 | 1 | _aCutlip, Donald E | |
| 700 | 1 | _aSimonton, Charles A | |
| 700 | 1 | _aSood, Poornima | |
| 700 | 1 | _aKereiakes, Dean J | |
| 773 | 0 |
_tJournal of the American College of Cardiology _gvol. 58 _gno. 1 _gp. 19-25 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.jacc.2011.02.022 _zAvailable from publisher's website |
| 999 |
_c20779199 _d20779199 |
||